Arthur W Baker1,2, Eileen K Maziarz1, Christopher J Arnold3, Melissa D Johnson1,2, Adrienne D Workman1, John M Reynolds4, John R Perfect1, Barbara D Alexander1,5. 1. Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina. 2. Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. 3. Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville. 4. Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina. 5. Duke University Clinical Microbiology Laboratory, Durham, North Carolina.
Abstract
BACKGROUND: Lung transplant recipients commonly develop invasive fungal infections (IFIs), but the most effective strategies to prevent IFIs following lung transplantation are not known. METHODS: We prospectively collected clinical data on all patients who underwent lung transplantation at a tertiary care academic hospital from January 2007-October 2014. Standard antifungal prophylaxis consisted of aerosolized amphotericin B lipid complex during the transplant hospitalization. For the first 180 days after transplant, we analyzed prevalence rates and timing of IFIs, risk factors for IFIs, and data from IFIs that broke through prophylaxis. RESULTS: In total, 156 of 815 lung transplant recipients developed IFIs (prevalence rate, 19.1 IFIs per 100 surgeries, 95% confidence interval [CI] 16.4-21.8%). The prevalence rate of invasive candidiasis (IC) was 11.4% (95% CI 9.2-13.6%), and the rate of non-Candida IFIs was 8.8% (95% CI 6.9-10.8%). First episodes of IC occurred a median of 31 days (interquartile range [IQR] 16-56 days) after transplant, while non-Candida IFIs occurred later, at a median of 86 days (IQR 40-121 days) after transplant. Of 169 IFI episodes, 121 (72%) occurred in the absence of recent antifungal prophylaxis; however, IC and non-Candida breakthrough IFIs were observed, most often representing failures of micafungin (n = 16) and aerosolized amphotericin B (n = 24) prophylaxis, respectively. CONCLUSIONS: Lung transplant recipients at our hospital had high rates of IFIs, despite receiving prophylaxis with aerosolized amphotericin B lipid complex during the transplant hospitalization. These data suggest benefit in providing systemic antifungal prophylaxis targeting Candida for up to 90 days after transplant and extending mold-active prophylaxis for up to 180 days after surgery.
BACKGROUND: Lung transplant recipients commonly develop invasive fungal infections (IFIs), but the most effective strategies to prevent IFIs following lung transplantation are not known. METHODS: We prospectively collected clinical data on all patients who underwent lung transplantation at a tertiary care academic hospital from January 2007-October 2014. Standard antifungal prophylaxis consisted of aerosolized amphotericin B lipid complex during the transplant hospitalization. For the first 180 days after transplant, we analyzed prevalence rates and timing of IFIs, risk factors for IFIs, and data from IFIs that broke through prophylaxis. RESULTS: In total, 156 of 815 lung transplant recipients developed IFIs (prevalence rate, 19.1 IFIs per 100 surgeries, 95% confidence interval [CI] 16.4-21.8%). The prevalence rate of invasive candidiasis (IC) was 11.4% (95% CI 9.2-13.6%), and the rate of non-Candida IFIs was 8.8% (95% CI 6.9-10.8%). First episodes of IC occurred a median of 31 days (interquartile range [IQR] 16-56 days) after transplant, while non-Candida IFIs occurred later, at a median of 86 days (IQR 40-121 days) after transplant. Of 169 IFI episodes, 121 (72%) occurred in the absence of recent antifungal prophylaxis; however, IC and non-Candida breakthrough IFIs were observed, most often representing failures of micafungin (n = 16) and aerosolized amphotericin B (n = 24) prophylaxis, respectively. CONCLUSIONS: Lung transplant recipients at our hospital had high rates of IFIs, despite receiving prophylaxis with aerosolized amphotericin B lipid complex during the transplant hospitalization. These data suggest benefit in providing systemic antifungal prophylaxis targeting Candida for up to 90 days after transplant and extending mold-active prophylaxis for up to 180 days after surgery.
Authors: D Neofytos; S Treadway; D Ostrander; C D Alonso; K L Dierberg; V Nussenblatt; C M Durand; C B Thompson; K A Marr Journal: Transpl Infect Dis Date: 2013-02-21 Impact factor: 2.228
Authors: Seyedmojtaba Seyedmousavi; Johan W Mouton; Paul E Verweij; Roger J M Brüggemann Journal: Expert Rev Anti Infect Ther Date: 2013-09 Impact factor: 5.091
Authors: Aniket Vadnerkar; Cornelius J Clancy; Umit Celik; Samuel A Yousem; Dimitra Mitsani; Yoshiya Toyoda; Minh-Ly Nguyen; Eun J Kwak; Joseph Pilewski; Fernanda P Silveira; Maria Crespo; M Hong Nguyen Journal: Transplantation Date: 2010-01-27 Impact factor: 4.939
Authors: Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger Journal: Clin Infect Dis Date: 2009-05-15 Impact factor: 9.079
Authors: Palash Samanta; Cornelius J Clancy; Rachel V Marini; Ryan M Rivosecchi; Erin K McCreary; Ryan K Shields; Bonnie A Falcione; Alex Viehman; Lauren Sacha; Eun Jeong Kwak; Fernanda P Silveira; Pablo G Sanchez; Matthew Morrell; Lloyd Clarke; M Hong Nguyen Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079
Authors: John E McGinniss; Samantha A Whiteside; Aurea Simon-Soro; Joshua M Diamond; Jason D Christie; Fredrick D Bushman; Ronald G Collman Journal: J Heart Lung Transplant Date: 2021-05-07 Impact factor: 13.569
Authors: Manuela Carugati; Letizia Corinna Morlacchi; Anna Maria Peri; Laura Alagna; Valeria Rossetti; Alessandra Bandera; Andrea Gori; Francesco Blasi; Ifalt Working Group Journal: Int J Mol Sci Date: 2020-02-12 Impact factor: 5.923